Label Changes for:

Increlex (mecasermin [rDNA origin]) injection

June 2012

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2012

 

 

ADVERSE REACTIONS

Post-Marketing Experience
  • Skin and Subcutaneous Tissue Disorders: alopecia, hair texture abnormal

 

Hide
(web1)